Financial Tearsheet

Company Overview

Alimera is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and affect millions of people in our aging populations.

Recent Financial News

Date   Headline
May 27, 2021 Alimera Sciences, Inc. to Present at the Summer Solstice – Best Ideas from the Buy Side Conference on June 2, 2021
May 17, 2021 Alimera Sciences Appoints David Dyer, M.D. as Chief Retina Specialist
Apr 28, 2021 Alimera Sciences Announces First Quarter 2021 Financial Results
Apr 22, 2021 Alimera Sciences to Report First Quarter 2021 Financial Results on Wednesday, April 28, 2021 and Provide Corporate Update
Apr 14, 2021 Alimera Sciences Receives $20 Million From Ocumension Therapeutics

IR Contacts

Investor Relations Transfer Agent

Cindy Rizzo, CORE IR
516 222 2560
Email: ir@alimerasciences.com

AST Financial, Bryan Anderson,
Relationship Manager
banderson@astfinancial.com
Auditors Corporate Counsel

Grant Thornton LLP
Joseph Heatherly, Partner
Joseph.Heatherly@us.gt.com

Charles Vaughn,
Nelson Mullins
(404) 322-6189
charles.vaughn@nelsonmullins.com

Stock Performance

Today's Open 9.75
Volume 25,964
Day Range 9.26 - 9.76
52 Week Range 3.82 - 12.25
Bid/Ask 9.35 / 9.51
Bid/Ask Size 100 X 100
Previous Close 9.81
Market Cap 47.79 million
Shares Outstanding 5.03 million
Dividend/Yield 0.00 / 0.00%
EPS (TTM) -1.840000
P/E Ratio (TTM) N/A

Recent XBRL Filings

Filing Date Form Type Description View
May 07, 2021 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  
Mar 05, 2021 10-K Annual report htmlhtml   pdfpdf   xbrlxbrl  
Nov 03, 2020 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  
Aug 04, 2020 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  
May 06, 2020 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  

Management Team

Rick Eiswirth, President and Chief Executive Officer

Philip Ashman, COO, Senior VP, Commercial Operations Europe

Dave Holland, CMO, Senior VP Corporate Communications & Managed Markets

Phil Jones, Chief Financial Officer

David Dyer, M.D., Chief Retina Specialist

Board of Directors

Rick Eiswirth, President and Chief Executive Officer

Brian Halak, Ph.D., B.S.E., Partner at Domain Associates, L.L.C. and CEO of WindMIL Therapeutics

Garheng Kong, M.D., Ph.D., Managing Partner, Sofinnova HealthQuest

James R. Largent, M.B.A., Lead Independent Director

Dan Myers, Non-Executive Chairman of the Board, interim CEO of Leo Lens Pharma

Peter J. Pizzo, III, Chief Financial Officer, ControlRad

John Snisarenko, Chief Commercial Officer, Oyster Point Pharma

Mary T. Szela, M.B.A., B.S.N., Chief Executive Officer and President, Surefire Medical, Inc.